Shkreli Rubs Salt in KaloBios Pharma (KBIO) Short Sellers' Wounds
Tweet
Share
E-mail
Get Alerts KBIO Hot Sheet
Join SI Premium – FREE
KaloBios Pharma (NASDAQ: KBIO) new CEO Martin Shkreli just tweeted a picture of himself and others at the company's headquarters captioned "turnaround in progress."
Shares have surged from $0.90 to over $45 in a few days amid news a Shkreli group has accumulated nearly the entire float and will takeover as CEO, staving off a wind-down. An epic short squeeze has ensued.
Turnaround in progress. $KBIO pic.twitter.com/5dseMG3B8I
— Martin Shkreli (@MartinShkreli) November 23, 2015Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns
- Gildan responds to short seller report, reiterates 2026 guidance
- Gildan Activewear (GIL) Mentioned as short at Jehoshaphat Research
Create E-mail Alert Related Categories
Management Comments, Momentum Movers, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
